Huntington's disease (HD) is a hereditary neurodegenerative ... The movement disorder is characterized by involuntary movements known as chorea, and by the impairment of voluntary movements. The ...
Clinical Trials Arena on MSN15d
Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adultsNeurocrine Biosciences has commenced the Phase I clinical trial of its oral, small molecule vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-1140675 in healthy adults. The trial aims to assess ...
SOM3355 (bevantolol hydrochloride) hit its objectives in a phase 2 trial in patients with Huntington's disease, improving the involuntary, jerky movements known as chorea that are a key symptom of ...
Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...
The fellows gain expertise in diagnosing and treating Parkinson’s disease, atypical Parkinsonian syndromes, dystonia, tremor, Huntington’s disease, chorea, myoclonus, ballism, Tourette syndrome, tics, ...
In 2023, the company received FDA approval for valbenazine as a treatment for chorea associated with Huntington's disease. Valbenazine is in Phase 3 clinical studies as an adjunctive treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback